Rituximab Plus Combination Chemotherapy in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma

Sponsor
Lymphoma Trials Office
Study ID
NCT00031902
Phase
PHASE1
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • bleomycin sulfate — BIOLOGICAL
  • rituximab — BIOLOGICAL
  • prednisolone — DRUG
  • vincristine sulfate — DRUG

Study Details

RATIONALE: Monoclonal antibodies such as rituximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining rituximab with chemotherapy may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of rituximab plus combination chemotherapy in treating patients who have HIV-related non-Hodgkin's lymphoma.

Key Dates

Start date
Oct 31, 2001
Status verified
Feb 2003

Study Design

Primary purpose
TREATMENT

Related Studies